WHO WE ARE

The Geneva Foundation is a non-profit organization that supports and advances innovative medical research and excellence in education within the U.S. military. We build enduring partnerships dedicated to the health and well-being of U.S. service members, their families, and the global community. Through these partnerships, Geneva connects military Investigators to research opportunities in a variety of therapeutic areas. We strive to work hand-in-hand with our partners to shape the future of military medicine.

In 2013, The Geneva Foundation celebrated its 20th anniversary. It has been rewarding and affirming to see how much we have grown, starting as a two-person business dedicated to supporting clinical trials locally at Madigan Army Medical Center, and developing into a 450+ person organization supporting research in over 50 military treatment facilities and federal laboratories around the world. Our accomplishments and our growth are inspiring and speak to the commitment of our employees and researchers to Geneva’s mission to advance medical research in the military.

Although Geneva has many reasons to celebrate, it seems fitting to mention that 2013 was also the toughest year in our 20-year history, as we adapted to the challenges imposed by the Federal government’s sequestration and shutdown. This was by no means an easy year. I am proud of Geneva’s ability to face these uncertain circumstances head-on, remaining nimble and embracing our core values as we navigated a particularly challenging landscape.

As we have learned over these 20 years, with challenges come opportunities, and Geneva is more enthusiastic than ever about the power of partnerships. Geneva partners with our Board of Directors and our Scientific Advisory Board, who provide valuable depth and vision to ensure Geneva’s vitality and long-term effectiveness. Geneva partners with world-renowned researchers, dedicated sponsors, and highly-skilled research and administrative professionals, all working toward the common goal of advancing military medicine on a global scale. As we look ahead to the next 20 years, we will continue these partnerships as well as foster new collaborations.

2013 also marked the first year of Geneva’s 5-year Strategic Plan, which is focused on expanding Geneva’s impact geared towards expanding our reach by remaining agile and responsive to the needs our service members. Since 1993, I never once doubted Geneva’s potential, and I remain deeply committed to that potential. Geneva, through our history of challenges, opportunities, and partnerships, is poised, ready, and more excited than ever for what the future holds.

From Our Founder

Jane Taylor, BSN | Founder
THE GENEVA FOUNDATION recognizes excellence in employees who go above and beyond the normal scope of their work, demonstrate Geneva’s core values, and strengthen our mission of promoting and supporting the advancement of military medicine. The Wave The Flag Award is a quarterly award given to an employee who exceeds expectations and exhibits Geneva’s core values of integrity, superior customer service, quality, innovation, teamwork, and respect for all.

WAVE THE FLAG QUARTER 1 RECIPIENT:
BRIGIT CICCARELLO, PROGRAM OFFICER
Site: Telemedicine and Advanced Technology Research Center (TATRC)
Location: Fort Detrick, MD
Years of Service: 7

“Brigit has always been a superlative employee, performing top quality work. She stays current with regulatory guidance, and provides support and assistance to Principal Investigators and government managers alike... She has gone above and beyond the requirements of her job... She is superior in every respect, and fully deserving of recognition.”

WAVE THE FLAG QUARTER 2 RECIPIENT:
KRYS TAL VALDEZ-DELGADO, RESEARCH COORDINATOR
Site: U S Army Institute of Surgical Research (USAISR)
Location: San Antonio, TX
Years of Service: 2

“Krystal became instrumental in managing the Preceptor Program for the entire Army Burn Center. She rapidly assimilated the materials needed to begin data collection so that valuable information was not lost. Krystal brings a number of unique skills to this project, elements of research coordination that we underestimated during our planning phase. Krystal is the glue that keeps our project on track.”

WAVE THE FLAG QUARTER 3 RECIPIENT:
KATHY ROBINSON, GRANTS & CONTRACTS MANAGER
Site: Corporate Office
Location: Tacoma, WA
Years of Service: 4

“Kathy is constantly going above and beyond. She pushes the studies in her portfolio into success with perseverance and determination. Kathy has developed special relationships with every investigator she works with. Kathy is a wealth of knowledge and overflows with the core values of integrity, superior customer service, quality, and innovation in everything she does.”

WAVE THE FLAG QUARTER 4 RECIPIENT:
HÉCTOR RUIZ, SHAREPOINT DESIGNER
Site: Corporate Office
Location: Tacoma, WA
Years of Service: 2

“Héctor tirelessly balances the needs of all departments at The Geneva Foundation. He always has a positive attitude and is an excellent and patient teacher. Héctor not only provides a valuable product to Geneva, he does so in a way that ensures employees enjoy learning and using the electronic collaboration and document management tools hosted on Geneva’s employee website and Intranet.”

INTEGRITY, SUPERIOR CUSTOMER SERVICE, QUALITY, INNOVATION, TEAMWORK, AND RESPECT FOR ALL
WHAT WE DO

Geneva has specialized capabilities in supporting federally funded and industry funded research, including researcher-initiated programs, sponsor-initiated programs and FDA-regulated, multi-center clinical trials. Geneva’s services also include educational grant management, and event planning. In each of these activities, Geneva works with our partners in the Army, Navy, and Air Force from idea inception through the final completion of the program. We strive to create relationships that result in the successful conduct of the program and a lasting partnership with the research team and sponsor.

FIVE LARGEST AWARDS (1993 - 2013)

1. INVESTIGATIONAL RESEARCH OMNIBUS CONTRACT
   Funded by Naval Medical Logistics Command (NMLC) in support of the Clinical Investigation Program (CIP), which is a component of U.S. Navy Bureau of Medicine and Surgery (BUMED)

2. MEDICAL RESEARCH PROJECT MANAGEMENT AND SCIENTIFIC/TECHNICAL SUPPORT SERVICES
   Funded by the US Army Medical Research and Materiel Command (USAMRMC) in support of the Telemedicine & Advanced Technology Research Center (TATRC), an office of the Headquarters of USAMMRC

3. ADVANCED DEVELOPMENT OF HEMORRHAGIC FEVER VIRUS THERAPEUTICS
   Dr. Sina Bavari, US Army Medical Research Institute for Infectious Diseases (USAMRIID)
   Funded by Sarepta Therapeutics, Inc.

4. ADVANCED DEVELOPMENT OF A CANDIDATE COMBINATION DNA VACCINE FOR HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) CAUSED BY HANTAVIRUSES (CATEGORY A PRIORITY PATHOGEN) USING A CROSS-CUTTING DELIVERY TECHNOLOGY TO ACCELERATE PROTECTIVE IMMUNE RESPONSES
   Dr. Connie Schmaljohn and Dr. Amy Shurtleff, US Army Medical Research Institute for Infectious Diseases (USAMRIID)
   Funded by National Institute of Allergy and Infectious Diseases under Contract Award No. HHSN272201200019C

5. BRAIN INJURY BIOMARKERS AND BEHAVIORAL CHARACTERIZATION ON MILD TRAUMATIC BRAIN INJURY IN SOLDIERS FOLLOWING REPEATED, LOW-LEVEL BLAST EXPOSURE
   Dr. Gary Kamioner, Walter Reed Army Institute of Research (WRAIR)
   Funded by CDMRP Deployment Related Medical Research Program Advanced Technology/Therapeutic Development Award under Award No. W81XWH-09-2-0055

FIVE LARGEST AWARDS IN 2013

1. SECOND GENERATION SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS
   Dr. Sina Bavari, US Army Medical Research Institute of Infectious Diseases (USAMRIID)
   Funded by National Institute of Allergy and Infectious Diseases’ Cooperative Research Partners for Biodefense (U01) Award under Award No. U01AI082051

2. STABLE NUCLEIC ACID LIPID PARTICLE (SNALP) LIPID NANOPARTICLES (LNP) ENABLEMENT OF SRNA THERAPY FOR HEMORRHAGIC FEVER INDUCED BY EBOLAVIRUS STRAIN ZAIRE (ZEBOV) INFECTION
   Dr. Sina Bavari, US Army Medical Research Institute of Infectious Diseases (USAMRIID)
   Funded by Tekmira Pharmaceuticals Corporation

3. PRECLINICAL ASSESSMENT OF MULTI-HEAD ELECTROPORATION DEVICE FOR DELIVERY OF BIODEFENSE DNA VACCINES
   Dr. Connie Schmaljohn, US Army Medical Research Institute of Infectious Diseases (USAMRIID)
   Funded by National Institute of Allergy and Infectious Diseases’ Partnerships for Development of Vaccine Technologies (RO1) Award under Award No. R01AI105383

4. IMPROVED FIELD MANAGEMENT AND SAFE GROUP TRANSPORT OF PATIENTS WITH HEAD AND SPINE INJURIES
   Dr. Khalid Barazanji, US Army Aeromedical Research Laboratory (USAARL)
   Funded by the Office of the Assistant Secretary of Defense (for Health Affairs) through the Combat Casualty Care Research Program under Award No. W81XWH-13-2-0047

5. AUTOLOGOUS SKIN CELL SPRAY FOR MASSIVE SOFT TISSUE WOUND INJURIES: A PROSPECTIVE, CASE-CONTROL, MULTICENTER TRIAL
   Dr. Mark Fleming, Walter Reed National Military Medical Center (WRNMMC)
   Funded by CDMRP Peer Reviewed Orthopaedic Research Program Clinical Trial Award under Award No. W81XWH-13-2-0031
2013 Timeline

**February**
Geneva hosts community event, Join the Conversation, featuring Dr. Dusten Macdonald, a Geneva researcher and radiation oncologist at Madigan Army Medical Center.

**March**
Geneva receives 3 TriService Nursing Research Program awards to be conducted at Brooke Army Medical Center, Tripler Army Medical Center, and William Beaumont Army Medical Center.

**May**
Geneva’s Community Giving Program supports Joint Base Lewis McChord’s Retiree Health Fair, Naval Medical Center San Diego’s Annual Primary Care Symposium, and Madigan Army Medical Center’s Nurses Week.

**June**
Geneva hosts the 8th annual National Liver Conference in San Antonio, TX.

**August**
Geneva adds dedicated regulatory personnel in-house to support clinical trials research.

**September**
Geneva receives 28 new awards from sponsors, including the National Institutes of Health, Telemedicine & Advanced Technology Research Center, and United States Army Medical Research Acquisition Activity.

**October**
Geneva initiates its 700th clinical trial.

**November**
Geneva submits its 68th proposal for the year to the National Institutes of Health.

**December**
Geneva hires its 150th employee for the year.

---

**Number of Geneva Employees**

- **2013:** 351 employees
- **1993:** 2 employees
- **1996:** 3 employees
- **2003:** 56 employees
- **2004:** 81 employees
- **2005:** 81 employees
- **2006:** 89 employees
- **2008:** 147 employees
- **2010:** 210 employees
- **2011:** 230 employees
- **2013:** 351 employees

---

**2014 National Defense Authorization Act** is signed into law which includes language to officially extend privileges to Geneva in order to work directly with the Uniformed Services University of the Health Sciences.
Dr. Don Johnson is a professor and the Director of Research at USAGPAN. He has received numerous grants that have been administered by Geneva since 1993, including grants funded by the TriService Nursing Research Program (TSNRP) and the American Nurses’ Association Foundation. Dr. Johnson has been involved in research for over thirty years, primarily in educational and animal research.

Dr. Don Johnson is a long-time Geneva nurse researcher, having partnered with Geneva since its founding in 1993. His first study with Geneva was an AIDS prevention study, which aimed to determine if it was possible to predict those individuals who were high risk. The success of this study led to subsequent studies, which looked at the role education plays in preventing individuals from contracting AIDS. Dr. Johnson established peer-led educational groups aimed at college-aged Hispanic males in ROTC programs in South Texas and Southern California. The results of this study were very positive, especially when compared to the more conventional approach that relied on experts to dispense advice and knowledge and during a time when AIDS was on the rise, especially in communities that lacked the knowledge to take precautions.

Dr. Johnson has served as the Director of Research at USAGPAN for 12 years. According to Dr. Johnson, his greatest accomplishment during his tenure is helping to make USAGPAN the top anesthesia program in the country. The program is actively engaged in identifying trends and in researching cutting edge practices designed to determine the best-practice model and evidence for practice in order to improve nursing and medicine.

Regarding his partnership with Geneva, Dr. Johnson reports that Geneva “always knows how to get things moving, cuts through the bureaucracy, gets it done, and helps with roadblocks”. His program manager has a “way of determining if grant proposals clearly state what’s intended” and rarely does he not take the advice provided. Geneva is proud to continue our partnership with Dr. Johnson.

Dr. Forsberg is the Regenerative Medicine Department Head at the Naval Medical Research Center in Silver Spring, MD. There, as part of a collaborative group, he oversees DoD funded combat casualty research and mentors orthopaedic and general surgery residents in translational research. He spends the balance of his time engaged in the treatment of combat-related orthopaedic injuries at the Walter Reed National Military Medical Center while maintaining a busy orthopaedic oncology practice at the John Muir Cancer Center and National Cancer Institute.

Dr. Forsberg’s research efforts focus on the characterization, prevention, and treatment of combat-related heterotopic ossification, which is defined as bone formation at an abnormal anatomical site such as soft tissue. Dr. Forsberg’s work has contributed to the development of advanced osseointegrated solutions connecting the bone to an implant for amputees.

Dr. Forsberg’s work in bioinformatics has also helped with the treatment and healing of severe extremity wounds. He has recently analyzed cell proteins in traumatic wounds as a method to help determine the readiness of a wound for closure without subsequent rupture of the wound at the suture site. With this information, orthopaedic surgeons can close traumatic wounds earlier with a substantially decreased risk of wound rupture.

“I believe we have an obligation to preserve the knowledge gained from over a decade of war for use if/when it is needed. Our relationship with Geneva gives us that opportunity.”
HOW WE DO IT

Geneva builds lasting collaborations with researchers, research teams, and sponsors through our holistic approach to facilitating research in a military setting. This approach focuses on maintaining an efficient, streamlined, and relationship-driven process that provides the researcher with the tools needed to facilitate exceptional research programs. Geneva sets itself apart by offering our partners a high level of service and expertise through our commitment to shared values of integrity, superior customer service, quality, teamwork, innovation, and respect for all.

Geneva is founded by Jane Taylor, a critical care nurse, to support and promote the advancement of military medicine and to serve the needs of Madigan Army Medical Center.

Geneva supports military researchers by managing industry-sponsored clinical trials, coordinating conference activities, and administering proffered gifts of equipment and travel.

Geneva commences management of first federal grant award from TriService Nursing Research Program, on behalf of nurse researchers at Madigan Army Medical Center.

Geneva sponsors first conference, the Kimbrough Urological Seminar, on behalf of the Society of Government Service Urologists.

Geneva negotiates a master agreement for research and development with the U.S. Army.

Geneva receives first National Institutes of Health awards at Walter Reed Army Institute of Research.

Geneva supports first international study on the development of a Malaria vaccine at Armed Forces Research Institute of Medical Services in Thailand.

Geneva’s current President, Elise Huszar, is hired as its first Executive Director.

Board of Directors approves Geneva to begin providing formal proposal development services, which creates a unique service not provided by similar non-profit organizations.

Geneva sponsors first conference, the Kimbrough Urological Seminar, on behalf of the Society of Government Service Urologists.

Geneva negotiates a master agreement for research and development with the U.S. Army.

Geneva receives first National Institutes of Health awards at Walter Reed Army Institute of Research.

Geneva receives a Congressional Special Interest award to establish Centers for Targeted Radiation Therapy to treat cancer at Madigan Army Medical Center and the VA Puget Sound Health Care system.

Geneva receives a Congressional Special Interest award to establish Centers for Targeted Radiation Therapy to treat cancer at Madigan Army Medical Center and the VA Puget Sound Health Care system.

Geneva’s growth leads to the formation of the Scientific Advisory Board, which provides expert-level review, deliberation, and guidance on topics in relevant areas of research.

The Federal Acquisition Activity Department is created, which is responsible for pursuing and managing federally-funded support contracts.
The Board of Directors ensures that Geneva achieves its mission to support the advancement of military medicine, now and in the years to come. Their oversight is fundamental in ensuring the viability and sustainability of Geneva, and they remain committed to successfully meeting their fiduciary obligations and governance responsibilities. Geneva’s Board members embrace their responsibilities graciously, engage productively, and contribute generously. Geneva thrives as a result of its Board members who truly appreciate the honor and opportunity of serving on the Board. Thanks to their dedication, Geneva is strategically positioned to accomplish great things today, with eyes toward the future.

Michael W. Hansch
Chairman
Years of Service: 10

Scott O’Halloran, JD
Board Member
Years of Service: 4

Linda Nguyen
Board Member
Years of Service: 2

Cliff Robertson, MD, MBA
Board Member
Years of Service: 7

David Blanford, CPA
Treasurer
Years of Service: 2

David Little, JD
Board Member
Years of Service: 2

Elise W. Huszar, MBA
Secretary, President
Years of Service: 18

David Shoultz, PhD, MBA
Board Member, SAB Chairman
Years of Service: 4

Colonel (Ret) Patrick Steel, MA
Board Member
Years of Service: 4

Major General (Ret.) Frank Scoggins
Board Member
Years of Service: 3

Jane S. Taylor, BSN
Board Member, Founder
Years of Service: 20

David A. Little, JD
Board Member
Years of Service: 2
Scientific Advisory Board

The Scientific Advisory Board (SAB) was established to further Geneva’s mission of advancing military medicine through innovative research. The SAB provides scientific consult, advisement, and direction to Geneva’s senior leadership, program directors, principal investigators, and research administrators. The SAB serves as a strategic partner alongside the investigator to ensure the science remains relevant, sustainable, and innovative. Geneva’s SAB currently consists of seven independent members who are proficiently knowledgeable and competent in one or more of the scientific or technical disciplines appropriate to the understanding of military medical research.

Geneva has managed over $175 million in federal grants & contracts since 1996
IN 2013, GENEVA MANAGED OVER $37M IN RESEARCH IN COLLABORATION WITH A VARIETY OF FEDERAL GOVERNMENT AGENCIES, CORPORATIONS, FOUNDATIONS, UNIVERSITIES, AND OTHER PARTNERS. IN ADDITION TO THE SPONSORS AND SUPPORTERS NAMED HERE, GENEVA IS DEEPLY GRATEFUL TO THOSE WHO SUPPORT AND CONTRIBUTE TO THE SUCCESS OF GENEVA’S NUMEROUS RESEARCH PROGRAMS WITHIN THE MILITARY MEDICAL COMMUNITY.

THANK YOU TO GENEVA’S 2013 SPONSORS AND COLLABORATING PARTNERS INCLUDING:

- AbbVie
- Actuated Medical, Inc.
- Agency for Healthcare Research & Quality
- Air Force Research Lab
- American College of Radiology
- American University
- Argos Therapeutics, Inc.
- Army Research Office
- Artrex
- AstraZeneca
- Auris Medical Inc.
- AxoGen Inc.
- Bayer
- Boehringer Ingelheim
- Brain Trauma Foundation
- Bristol-Myers Squibb
- Catholic University of America
- CEL SCI
- Cempra Inc.
- CFD Research
- Children’s Oncology Group (COG)
- Clinical Research Management, Inc.
- Combat Casualty Care Research Program
- Congruently Directed Medical Research Program
- Creare, Inc.
- CSA Medical Inc.
- Devcom
- Flexion Therapeutics, Inc.
- Georgia Regents University
- Gilead
- Grifols Inc.
- Histogenics
- INC Research, Inc.
- Integrated Biotherapeutics
- Jansen Research & Development
- Johns Hopkins University
- Lieber Institute for Brain Development
- Lovelace Respiratory Research Institute
- Mauna Kea Technologies
- Mayo Clinic
- MDDX Research & Informatics
- Medpace
- Medtronic
- Microbiotix, Inc.
- Military Operational Medicine Research Program
- Military Suicide Research Consortium
- Musculoskeletal Transplant Foundation
- NanoTherapeutics, Inc.
- National Cancer Institute
- National Institute of Allergy & Infectious Diseases
- National Institutes of Health
- Naval Medical Logistics Command
- Neurex Pharmaceuticals Ltd.
- NeuroKinetics, Inc.
- Northwestern University
- Novartis
- Novo Nordisk
- NuVasive, Inc.
- Orthopaedic Trauma Association
- PAREXEL
- Pharmaceutical Product Development, LLC
- PneumRx
- Portland State University
- Portland VA Research Foundation
- PRA Health Sciences
- Pliyor Medical Devices, Inc.
- Rho, Inc.
- RTI Surgical Inc.
- Sarepta Therapeutics, Inc.
- SanoCell NeuroSens
- SFI Pharmaceuticals Group
- SIVARIS Inc.
- Smith & Nephew
- Southeast Regional Contracting Office
- Southern Illinois University
- State University of New York
- Striker Pharmaceuticals, Ltd
- Tekmira Pharmaceuticals Corporation
- Temple University
- The Telemedicine & Advanced Technology Research Center
- Ther-Rx Corporation
- Theorem Clinical Research
- TR Service Nursing Research Program
- U.S. Army Medical Research & Materiel Command
- University of Alabama at Birmingham
- University of California Los Angeles
- University of California San Diego
- University of Nebraska
- University of Pennsylvania
- University of Pittsburgh Medical Center
- University of Texas Health Science Center San Antonio
- University of Washington
- VentRx Pharmaceuticals, Inc.
- Veritas Biosciences, Inc.
- Wyeth Pharmaceuticals
- Xbiotech USA, Inc.
- Zimmer

"I believe in collaboration and high-quality innovation and research to improve the lives of the combat injured and ill and their families. I do translational research to solve problems the wounded warriors and their families have, to better their survival and their lives long-term. We aim to change clinical practice. We work with civilian and military partners. We work with investigators in the Army, Navy, and Air Force, and with physicians, nurses, and basic scientists. As strong, expert research teams, we produce practice-changing innovation through our partnership with Geneva."

"It’s a partnership. As a military academic physician, you are unable to obtain some of your goals without partnering with an organization like The Geneva Foundation. Geneva is an extension of what we do academically and allows us to do far more than we could ever possibly do in research and continuing education alone."

Geneva has partnered with Dr. Harrison by hosting the National Liver Conference (NLC), a conference that connects world-renowned Hepatology experts with providers from the military, industry, and civilian sectors to advance the understanding and treatment of liver disease. Geneva’s commitment to superior service, innovation, and teamwork coupled with Dr. Harrison’s great vision has led NLC to become a premier conference serving the Hepatology community. Geneva truly values and appreciates Dr. Harrison’s expertise as a physician, renowned speaker, and leader in the field of Hepatology.

Geneva has also partnered with Dr. Harrison by hosting the National Liver Conference (NLC), a conference that connects world-renowned Hepatology experts with providers from the military, industry, and civilian sectors to advance the understanding and treatment of liver disease. Geneva’s commitment to superior service, innovation, and teamwork coupled with Dr. Harrison’s great vision has led NLC to become a premier conference serving the Hepatology community. Geneva truly values and appreciates Dr. Harrison’s expertise as a physician, renowned speaker, and leader in the field of Hepatology.

Lt Col Vikhyat Bebarta, USAF, MC
Chief Division of Medical Toxicology, Department of Emergency Medicine
San Antonio Military Medical Center (SAMMC)
Years of Service with Geneva: 6

Dr. Vik Bebarta is a board-certified emergency physician and a fellowship-trained and board-certified medical toxicologist. He is the Director of the Air Force Enroute Care Research Center at US Army Institute of Surgical Research and the Chief of Medical Toxicology and an academic staff emergency physician at SAMMC. He is also the Director of the Clinical Research, Emergency Sciences, and Toxicology (CREST) Research Program. Dr. Vik Bebarta is an Associate Professor of Emergency Medicine at the Uniformed Services University of the Health Sciences.

Geneva has partnered with Dr. Vik Bebarta for more than six years on research projects in the areas of emergency medicine, combat casualty care, and toxicology. His first grant with Geneva studied the human response to acute and chronic hydrocodone administration to better understand how to treat pain, drug misuse, and overdose. Since then, he has been awarded four other federal grant and contract awards sponsored by the National Institutes of Health, Department of Defense, and other federal agencies.

Geneva is proud to facilitate Dr. Vik Bebarta’s work in the advancement of emergency medicine and toxicology science. He is a renowned emergency medicine physician respected by his patients and peers alike. Geneva is strongly committed to the success of Dr. Vik Bebarta’s research and provides dedicated program management to allow Dr. Bebarta to focus on finding new and better ways to deliver the right care at the right time based on sound scientific investigation.

"I believe in collaboration and high-quality innovation and research to improve the lives of the combat injured and ill and their families. I do translational research to solve problems the wounded warriors and their families have, to better their survival and their lives long-term. We aim to change clinical practice. We work with civilian and military partners. We work with investigators in the Army, Navy, and Air Force, and with physicians, nurses, and basic scientists. As strong, expert research teams, we produce practice-changing innovation through our partnership with Geneva."

COL Stephen Harrison, MD
Director of Graduate Medical Education
Brooke Army Medical Center (BAMC)
Years of Service with Geneva: 10

Dr. Stephen Harrison currently serves as Director of Graduate Medical Education at BAMC, Associate Dean for San Antonio Uniformed Services Health Education Consortium; Chief, Hepatology; Chief, Gastroenterology Research; and Gastroenterology Consultant to the Army Surgeon General. In his current position as Director of Graduate Medical Education, Dr. Harrison oversees all of the training and education activities at BAMC.

Geneva has partnered with Dr. Harrison for over 10 years on research projects and clinical trials in Hepatology and Gastroenterology. In 2013, Dr. Harrison completed 15 clinical trials with Geneva, accounting for 20% of Geneva’s clinical trials portfolio. Dr. Harrison’s cutting-edge research, in partnership with Geneva and numerous pharmaceutical companies, has led to several breakthroughs in Hepatology, including the remission of Hepatitis C in patients carrying the disease.

Geneva’s commitment to superior service, innovation, and teamwork coupled with Dr. Harrison’s great vision has led NLC to become a premier conference serving the Hepatology community. Geneva truly values and appreciates Dr. Harrison’s expertise as a physician, renowned speaker, and leader in the field of Hepatology.

“it’s a partnership. As a military academic physician, you are unable to obtain some of your goals without partnering with an organization like The Geneva Foundation. Geneva is an extension of what we do academically and allows us to do far more than we could ever possibly do in research and continuing education alone.”
FINANCIALS

Total Grant, Contract and Award Revenue............................................ $38,485,000

Program Expenses
Research and Education Expenses...................................................... $26,559,000
Payment to Subcontractors................................................................. $5,075,000
Total Program Expenses........................................................................ $31,634,000

Net Income from Grants, Contracts and Awards..................................... $6,851,000

Support Services
General and Administrative................................................................. $6,629,000
Fund Development................................................................................ $81,000
Total Support Services......................................................................... $6,710,000

Operating Income (loss)......................................................................... $141,000

Other Income........................................................................................ $56,000

Increase (decrease) in Net Assets......................................................... $197,000

Unrestricted Net Assets
Beginning of Year ............................................................................... $3,201,800
End of Year ......................................................................................... $3,398,800

The financials are presented on a pro-forma basis to reflect a change in estimate affecting prior periods.
WHY WE DO IT

The military’s medical research institutions are responsible for some of the nation’s most important discoveries in medicine, ranging from regenerative medicine for burn injuries to novel treatments for PTSD. These breakthroughs, have far-reaching implications that extend beyond the military community, shaping medicine on a national and global scale.

Innovative Treatments For Spinal Degeneration

CERVICAL SPONDYLOSIS, OR CERVICAL DEGENERATIVE DISC DISEASE, IS THE GRADUAL DETERIORATION OF THE DISCS BETWEEN THE VERTEBRAE IN THE CERVICAL SPINE. AT A MINIMUM, CERVICAL SPONDYLOSIS CAUSES NECK PAIN, NUMBNESS, AND LOSS OF FUNCTION. IT CAN OFTEN BE A DEBILITATING DISEASE, RESULTING IN SEVERE NECK PAIN AND POSSIBLE NEUROLOGICAL DAMAGE IN THE PATIENT.

In military populations, cervical spondylosis can prevent service members from achieving full restoration of function needed to serve our country. Research finds that degenerative cervical spine disorders will affect up to two-thirds of the U.S. population.

There are different treatment options available for patients with cervical spondylosis. Spinal fusion is a typical treatment for patients with severe pain who do not respond to non-operative treatment or who show increasing neurological problems. However, spinal fusion comes with many disadvantages, including loss of spinal mobility and accelerated degeneration of the adjacent discs.

An innovative alternate option to treating cervical spondylosis is NuVasive’s Porous Coated Motion (PCM) Cervical Disc, a disc replacement device. The PCM Cervical Disc aims to preserve mobility in the neck, while being minimally disruptive to the adjacent disks in the cervical spine. NuVasive, a medical device company, conducted a multi-site clinical trial to evaluate the safety and effectiveness of the PCM Cervical Disc as compared to spinal fusion in the treatment of patients with cervical spondylosis.

Madigan Army Medical Center (MAMC) was one of the 23 investigative sites across the country that participated in the Phase III study beginning in 2005. MAMC enrolled 30 study participants, which included military service members and their beneficiaries. Results of the study demonstrated excellent clinical outcomes in the treatment of cervical spondylosis. A majority of study participants reported decreased pain, improved neurological status, lower rates of dysphagia (difficulty swallowing), and greater patient satisfaction, all while maintaining motion in the neck. Patients who were greatly restricted in their movement and activity were able to return to their duties as well as active hobbies.

An active duty soldier was able to return to combat just two months after receiving the PCM Cervical Disc replacement. Another soldier, now retired, has been able to return to mountain climbing, long-distance running, and scuba diving with no limitation to his movement, activities he had not been able to participate in since the manifestation of his condition.

In October 2012, the FDA granted Premarket Approval (PMA) for the PCM Cervical Disc. In February 2013, NuVasive gained approval from the FDA for their PCM Post Approval Study that will continue to follow the patients for up to seven years after their surgery in order to determine the longer-term benefits of the PCM Cervical Disc.
REGENERATING LARGE SEGMENTS OF BONE FOLLOWING A TRAUMATIC COMBAT INJURY IS ONE OF THE MOST CHALLENGING MEDICAL PROBLEMS FACING WOUNDED WARRIORS TODAY. INJURIES RESULTING IN THE LOSS OF BONE ARE SEVERE AND COMPLEX IN NATURE, MAKING TREATMENT DIFFICULT AND SOMETIMES IMPOSSIBLE.

Among the many therapies currently in development to address these injuries are those that promote regeneration of bone and restoration of function by using donor bone tissue and marrow, otherwise known as an allogeneic tissue transplant. However, these techniques require lifelong immunosuppression in the patient, which can lead to increased infections and a greatly reduced quality of life.

Geneva Researcher LTC Luis Alvarez, PhD, Principal Investigator and Founder of the Regenerative Biology Research Group at the National Cancer Institute, is researching how to stimulate bone regeneration in wounded warriors without the use of a donor, thus eliminating the risk of lifelong immunosuppression. In 2011, Dr. Alvarez began a study with The Geneva Foundation that examined the role of mesenchymal stem cells (MSCs), stem cells that are capable of differentiating into bone precursors, at the injury site. However, the relative scarcity of MSCs in bone marrow (less than 0.01% of all nucleated bone marrow cells) prohibits widespread therapeutic use in most cases. The development of methods to expand a patient’s own MSCs at an injury site holds great promise for bone regeneration and subsequent quality of life in the wounded warrior. In addition to regenerating bone MSCs also serve as supportive cells that play an important role in regulating the immune system and inflammation.

In 2013, Dr. Alvarez’s study made notable progress by discovering a novel peptide sequence that enabled retention of growth factors at the injury site, thus increasing MSC production. As the unstable wound environment presents unique and specific challenges for proliferating MSCs, LTC Alvarez’s discovery has significant implications for bone regeneration as a whole. This platform technology now allows orthopedic implants to be rendered biologically active and able to support bone regeneration to an extent not previously possible.

By regenerating large segments of anatomically shaped, patient-specific functional human bone from engineered MSCs, Dr. Alvarez’s research has tremendous potential to transform bone reconstruction to treat congenital defects, cancers, and traumatic injuries in civilian and military populations. Currently, LTC Alvarez is devoting time to advance this platform technology into preclinical trials for segmental bone defects and spinal fusion applications.

TREATING DEPRESSION VIA TELEHEALTH

DESPITE INCREASED MENTAL HEALTH PROBLEMS IN THE MILITARY, IT IS ESTIMATED THAT ONLY 23–40% OF THOSE DIAGNOSED WITH PSYCHIATRIC DISORDERS SOUGHT TREATMENT IN THE YEAR PRIOR. PEOPLE FACE MANY OBSTACLES IN SEEKING TRADITIONAL MENTAL HEALTH TREATMENTS, INCLUDING GEOGRAPHIC, LOGISTICAL, AND FINANCIAL SETBACKS. THESE OBSTACLES ARE ONLY AMPLIFIED IN MILITARY POPULATIONS, WHERE THE STIGMA OF MENTAL ILLNESS ENCOURAGES A CULTURE OF SILENT SUFFERING. THE QUESTION REMAINS - HOW DO THOSE IN NEED RECEIVE THE CARE THEY NEED, ESPECIALLY AMONG POPULATIONS THAT NEED IT THE MOST?

The use of tele-behavioral health (TBH), via the internet, to support remote mental health care has the potential to reduce many of the barriers preventing those in need from pursuing or accessing care, and can be highly effective in the treatment of depression and other mental health issues. TBH treatments have several advantages over traditional in-person care, including increased, 24/7 access to care services, which is particularly important for patients living in remote or underserved areas. Patients are also able to receive care in the comfort, convenience, and privacy of their own homes, which is advantageous for patients who perceive the stigma surrounding traditional, in-person mental health care.

In 2011, Drs. Gregory Gahm and David Luxton initiated a study to evaluate the effectiveness of in-home, web-based TBH treatments to treat depression among military service members and veterans. This study compares two randomly-assigned groups of soldiers and veterans with depression. One group receives mental health treatment via webcam, while the other group receives treatment delivered in a traditional, in-person format. The investigators have hypothesized that the quality of care, clinical outcomes, degree of safety, and patient satisfaction will be equivalent between these two groups. Preliminary results suggest that the delivery of TBH treatment is feasible, safe, and has positive treatment outcomes.

The use of in-home, web-based TBH treatments has the potential to dramatically increase the availability and access to mental health care within the military population. This could make a significant contribution in addressing the current and future health needs of all service members, helping to ensure the well-being of our military forces, wherever they are located.

The use of in-home, web-based TBH treatments has the potential to dramatically increase the availability and access to mental health care within the military population.
GENEVA TODAY

At Geneva, we recognize that innovative collaboration is vital to medical advancement. We are proud to have built strong partnerships with industry and medical leaders, as well as with experienced and novice researchers, within a wide variety of therapeutic areas. Through these partnerships, exciting new ideas are developing. These ideas have the power to improve patient lives and to provide security for the health and well-being of U.S. service members, their families, and our global community.

USING EYE-SYNC TO DETECT TBI

Recent research finds that a person who sustains a concussion may incur various behavioral and cognitive disabilities with possible debilitating and lifelong consequences. Due to the nature of their activities, military personnel and athletes are among the most at risk for experiencing concussions and brain injuries. Based on existing data, veterans’ advocates believe that 10-20% of Operation Iraqi Freedom veterans, or 150,000-300,000 people, have some level of traumatic brain injury (TBI). Among wounded service members, the rate of TBI rises to 33%.

In an effort to better understand and assess brain function in individuals who have sustained Traumatic Brain Injuries, New York based non-Profit organization The Brain Trauma Foundation (BTF) is investigating the relationship between eye-tracking, attention, and predictive timing, all key factors in determining the cognitive performance levels needed for participation in demanding military and athletic activities. Made possible by a grant from the Department of Defense (DoD), the EYE-TRAC Advance (Eye-Tracking Rapid Attention Computation) study focuses on the use of a novel eye-tracking paradigm (EYE-SYNC) to tap into the attentional networks in the brain. The Geneva Foundation is supporting large scale recruitment efforts at Ft. Hood, with a goal of 5,000 active duty study participants.

Researchers at BTF have developed a customized portable eye-tracking “goggle” to better understand the relationship between normal and abnormal eye-tracking and various cognitive functions. These “goggles” are fully-integrated, head-mounted eye-trackers containing both the hardware and software systems used to administer the test and to store testing results. In less than one minute, the non-invasive EYE-SYNC test measures eye position variance relative to a predictable moving target stimulus. The ETA study will establish a normative database of eye-tracking results that can be used to provide a reliable, measureable representation of attention performance which can indicate a certain level of brain function.

In addition to studying normative eye-tracking performance with health military personnel, abnormal eye-tracking and cognitive performance following a concussion will also be studied in a cohort of 5,000 athletes. Testing is currently being conducted at Fort Hood, Texas, the US Army Research Institute of Environmental Medicine in Massachusetts, and at the Brain Trauma Foundation sites in New York City, Boston, and Palo Alto, CA.

Researchers at BTF have developed a customized portable eye-tracking “goggle” to better understand the relationship between normal and abnormal eye-tracking and various cognitive functions. These “goggles” are fully-integrated, head-mounted eye-trackers containing both the hardware and software systems used to administer the test and to store testing results. In less than one minute, the non-invasive EYE-SYNC test measures eye position variance relative to a predictable moving target stimulus. The ETA study will establish a normative database of eye-tracking results that can be used to provide a reliable, measureable representation of attention performance which can indicate a certain level of brain function.

The Brain Trauma Foundation’s EYE-SYNC eye-tracking paradigm has enormous potential in the detection of impaired performance in military operational environments and even at the sidelines of athletic events. EYE-SYNC may enable the rapid detection and assessment of soldier and athlete readiness and in the future could be further examined to distinguish specific conditions associated with attention impairment.

In addition to studying normative eye-tracking performance with health military personnel, abnormal eye-tracking and cognitive performance following a concussion will also be studied in a cohort of 5,000 athletes. Testing is currently being conducted at Fort Hood, Texas, the US Army Research Institute of Environmental Medicine in Massachusetts, and at the Brain Trauma Foundation sites in New York City, Boston, and Palo Alto, CA.

1 https://www.braintrauma.org/tbi-faqs/military-tbi/